Aquestive Therapeutics, Inc. (AQST)
4.61
+0.04
(+0.88%)
USD |
NASDAQ |
Oct 06, 16:00
4.61
0.00 (0.00%)
Pre-Market: 20:00
Aquestive Therapeutics EPS Diluted (Quarterly) : -0.1829 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1829 |
| March 31, 2026 | -0.0657 |
| December 31, 2025 | -0.2612 |
| September 30, 2025 | -0.1397 |
| June 30, 2025 | -0.1364 |
| March 31, 2025 | -0.2401 |
| December 31, 2024 | -0.187 |
| September 30, 2024 | -0.1264 |
| June 30, 2024 | -0.0302 |
| March 31, 2024 | -0.1743 |
| December 31, 2023 | -0.1184 |
| September 30, 2023 | -0.0315 |
| June 30, 2023 | -0.101 |
| March 31, 2023 | 0.1093 |
| December 31, 2022 | -0.2271 |
| September 30, 2022 | -0.2346 |
| June 30, 2022 | -0.3586 |
| March 31, 2022 | -0.3188 |
| December 31, 2021 | -0.7166 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.3711 |
| June 30, 2021 | -0.3336 |
| March 31, 2021 | -0.4126 |
| December 31, 2020 | -0.6022 |
| September 30, 2020 | -0.4923 |
| June 30, 2020 | -0.0695 |
| March 31, 2020 | -0.4924 |
| December 31, 2019 | -0.478 |
| September 30, 2019 | -0.7356 |
| June 30, 2019 | -0.8195 |
| March 31, 2019 | -0.5899 |
| December 31, 2018 | -0.5591 |
| September 30, 2018 | -0.636 |
| June 30, 2018 | -1.450 |
| March 31, 2018 | 0.1628 |
| December 31, 2017 | -0.4237 |
| September 30, 2017 | 0.3108 |
| June 30, 2017 | -0.2587 |
| March 31, 2017 | -0.0822 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | -1.017 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -22.86M |
| Revenue (Quarterly) | 13.82M |
| Total Expenses (Quarterly) | 36.68M |
| Enterprise Value | 629.20M |
| Gross Profit Margin (Quarterly) | 70.93% |
| Profit Margin (Quarterly) | -165.5% |
| Earnings Yield | -14.09% |
| Normalized Earnings Yield | -12.67 |